• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Diffusion Pharmaceuticals Inc. (Amendment)

    2/14/24 9:23:50 AM ET
    $DFFN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DFFN alert in real time by email
    SC 13G/A 1 d789294dsc13ga.htm SC 13G/A SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    CervoMed Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    15713L109

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Act”) or otherwise subject to the liabilities of the section of the Act but shall be subject to all other provisions of that Act (however, see the Notes).

     

     

     


    CUSIP No. 15713L109

     

     1.   

     NAMES OF REPORTING PERSONS

     

     AI EIPP Holdings LLC

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3.  

     SEC USE ONLY:

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION:

     

     State of Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5.    

     SOLE VOTING POWER:

     

     0

        6.   

     SHARED VOTING POWER:

     

     428,203(1)

        7.   

     SOLE DISPOSITIVE POWER:

     

     0

        8.   

     SHARED DISPOSITIVE POWER:

     

     428,203(1)

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

     428,203(1)

    10.  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

     

     7.49%(2)

    12.  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

     OO (Limited Liability Company)

     

    (1)

    Represents (i) 385,647 shares of the Issuer’s Common Stock, and (ii) 42,556 shares of Common Stock underlying pre-funded warrants held by AI EIPP Holdings, LLC exercisable at a price per share of $19.81, on or before April 2, 2028 (the “Warrants”).

    (2)

    Based on 5,674,520 shares of the Issuer’s Common Stock outstanding as of November 9, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 13, 2023.

     

    2


    CUSIP No. 15713L109

     

     1.   

     NAMES OF REPORTING PERSONS

     

     Access Industries Management, LLC

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3.  

     SEC USE ONLY:

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION:

     

     State of Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5.    

     SOLE VOTING POWER:

     

     0

        6.   

     SHARED VOTING POWER:

     

     428,203(1)

        7.   

     SOLE DISPOSITIVE POWER:

     

     0

        8.   

     SHARED DISPOSITIVE POWER:

     

     428,203(1)

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

     428,203(1)

    10.  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

     

     7.49%(2)

    12.  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

     OO (Limited Liability Company)

     

    (1)

    Represents (i) 385,647 shares of the Issuer’s Common Stock, and (ii) 42,556 shares of Common Stock underlying the Warrants.

    (2)

    Based on 5,674,520 shares of the Issuer’s Common Stock outstanding as of November 9, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 13, 2023.

     

    3


    CUSIP No. 15713L109

     

     1.  

     NAMES OF REPORTING PERSONS

     

     Len Blavatnik

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3.  

     SEC USE ONLY:

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION:

     

     United States of America

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5.    

     SOLE VOTING POWER:

     

     0

        6.   

     SHARED VOTING POWER:

     

     428,203(1)

        7.   

     SOLE DISPOSITIVE POWER:

     

     0

        8.   

     SHARED DISPOSITIVE POWER:

     

     428,203(1)

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

     428,203(1)

    10.  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

     

     7.49%(2)

    12.  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

     IN

     

    (1)

    Represents (i) 385,647 shares of the Issuer’s Common Stock, and (ii) 42,556 shares of Common Stock underlying the Warrants.

    (2)

    Based on 5,674,520 shares of the Issuer’s Common Stock outstanding as of November 9, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 13, 2023.

     

    4


    Schedule 13G

    CUSIP No. 15713L109

     

    Item 1.

     

      (a)

    Name of Issuer:

    CervoMed Inc. (the “Issuer”).

     

      (b)

    Address of Issuer’s Principal Executive Offices:

    20 Park Plaza, Suite 424

    Boston, Massachusetts 02216

     

    Item 2.

     

      (a)

    Name of Person Filing:

    This filing is being made on behalf of (collectively, the “Access Filers”):

    AI EIPP Holdings LLC (“AI EIPP”)

    Access Industries Management, LLC (“AIM”)

    Len Blavatnik

     

      (b)

    Address of Principal Business Office or, if none, Residence:

    The principal business office of each reporting person is c/o Access Industries, Inc., 40 West 57th Street, 28th Floor, New York, NY 10019.

     

      (c)

    Citizenship:

    Each of AI EIPP and AIM is a limited liability company organized under the laws of the State of Delaware.

    Mr. Blavatnik is a citizen of the United States of America.

     

      (d)

    Title of Class of Securities:

    Common Stock, par value $0.001 per share (“Common Stock”).

     

      (e)

    CUSIP Number:

    15713L109

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)    ☐    An investment adviser in accordance with §240.13d-1(b) (1)(ii)(E);
    (f)    ☐    An employee benefit plan or endowment fund in accordance with §240.13d-1(b) (1)(ii)(F);
    (g)    ☐    A parent holding company or control person in accordance with §240.13d-1(b) (1)(ii)(G);
    (h)    ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)    ☐    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
    (k)    ☐    Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

    Not Applicable.

     

    5


    Item 4.

    Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)

    Amount beneficially owned:

    See the responses to Item 9 on the attached cover pages.

     

      (b)

    Percent of class:

    See Item 11 of the attached cover pages. The percentages reported in Item 11 of the attached cover pages are based upon 5,674,520 shares of the Issuer’s Common Stock outstanding.

     

      (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote:

    See the responses to Item 5 on the attached cover pages.

     

      (ii)

    Shared power to vote or to direct the vote:

    See the responses to Item 6 on the attached cover pages.

     

      (iii)

    Sole power to dispose or to direct the disposition:

    See the responses to Item 7 on the attached cover pages.

     

      (iv)

    Shared power to dispose or to direct the disposition:

    See the responses to Item 8 on the attached cover pages.

    385,647 shares of Common Stock are owned directly by AI EIPP, as well as Warrants exercisable into 42,556 shares of Common Stock, which are deemed to be beneficially owned by AI EIPP pursuant to the terms of the warrant agreement (which limits the number of Warrants exercisable into Common Stock to an amount that would not result in the holder beneficially owning more than 9.99% of the outstanding Common Stock). Such shares of Common Stock may be deemed to be beneficially owned by AIM and Mr. Blavatnik because (i) AIM is the sole manager of AI EIPP and (ii) Len Blavatnik controls AIM and holds a majority of the outstanding voting interests in AI EIPP. Each of AIM and Mr. Blavatnik, and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐:

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not Applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the parent Holding Company or Control Person.

    Not Applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not Applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not Applicable.

     

    6


    Item 10.

    Certifications.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a–11.

     

    7


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 14, 2024

     

    AI EIPP HOLDINGS LLC     By: Access Industries Management, LLC, its Manager
       

    /s/ Alejandro Moreno

        Name:   Alejandro Moreno
        Title:   Executive Vice President
    ACCESS INDUSTRIES MANAGEMENT, LLC    

    /s/ Alejandro Moreno

        Name:   Alejandro Moreno
        Title:   Executive Vice President
       

    *

        Name:   Len Blavatnik

     

    *

    The undersigned, by signing his name hereto, executes this Schedule 13G pursuant to the Power of Attorney executed on behalf of Mr. Blavatnik and filed herewith.

     

    By:  

    /s/Alejandro Moreno

    Name:   Alejandro Moreno
      Attorney-in-Fact

     

     

    8

    Get the next $DFFN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DFFN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DFFN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma

    Approximately 71% of Stockholders Voted in Favor of the TransactionDiffusion Announces 1-for-1.5 Reverse Stock SplitMerger on Track to Close on August 16, 2023 CHARLOTTESVILLE, Va., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) today announced that its stockholders have voted to approve all proposals at a special meeting of stockholders held earlier today, including the issuance of Diffusion Common Stock in the pending merger with EIP Pharma Inc. ("EIP"), and a reverse stock split of outstanding Diffusion Common Stock (the "Reverse Split"). Dr. Robert Cobuzzi, President and Chief Executive Officer of Diffusion, said, "We are pleased with the outcome of to

    8/15/23 4:01:02 PM ET
    $DFFN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases

    Combined company will pursue late-stage clinical development of oral neflamapimod for the treatment of dementia with Lewy bodies EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging Combined company expected to have a cash runway through Phase 2b clinical data and to the end of 2024 Transaction has unanimous support of both EIP Pharma and Diffusion Boards of Directors BOSTON and CHARLOTTESVILLE, Va., March 30, 2023 (GLOBE NEWSWIRE) -- EIP Pharma Inc. (EIP Pharma), a privately held clinical-stage company focused on developing treatments for neurodegenerative diseases, and Diffusion Pharmaceuticals Inc. (D

    3/30/23 7:00:20 AM ET
    $DFFN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities

    LifeSci Special Opportunities Master Fund Announces Support for Diffusion's Ongoing, Board-led Strategic Review Process and for Diffusion's Nominees at 2022 Annual Meeting New Director to be Appointed to Diffusion Board if Strategic Transaction Not Completed by mid-2023 CHARLOTTESVILLE, Va., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing novel therapies that may enhance the body's ability to deliver oxygen to areas where it is needed most, today announced that it has entered into a settlement agreement with LifeSci Special Opportunities Master Fund Ltd., affiliated entities and cert

    12/16/22 6:30:48 AM ET
    $DFFN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DFFN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Boger Joshua S

    4 - CervoMed Inc. (0001053691) (Issuer)

    2/13/24 4:39:58 PM ET
    $DFFN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Boger Joshua S claimed ownership of 561,309 shares (SEC Form 3)

    3 - CervoMed Inc. (0001053691) (Issuer)

    2/9/24 4:31:45 PM ET
    $DFFN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Alam John J

    4 - CervoMed Inc. (0001053691) (Issuer)

    1/26/24 6:47:52 PM ET
    $DFFN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DFFN
    SEC Filings

    View All

    Diffusion Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - CervoMed Inc. (0001053691) (Filer)

    2/7/24 4:06:21 PM ET
    $DFFN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Diffusion Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits

    8-K - CervoMed Inc. (0001053691) (Filer)

    2/2/24 4:17:13 PM ET
    $DFFN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Diffusion Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - CervoMed Inc. (0001053691) (Filer)

    1/5/24 4:05:35 PM ET
    $DFFN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DFFN
    Leadership Updates

    Live Leadership Updates

    View All

    $DFFN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer

    CHARLOTTESVILLE, Va., May 18, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, today announced that Raven Jaeger, M.S., has joined the Company as its Chief Regulatory Officer effective immediately. Ms. Jaeger will be responsible for development and implementation of regulatory and related strategies to support the development and commercialization of Diffusion's product development candidates, including the Company's lead candidate, trans sodium crocetinate (TSC), which is planned for development as an adju

    5/18/22 7:30:00 AM ET
    $DFFN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Diffusion Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

    Completed Dosing in Altitude Trial; Topline Data Expected in June 2022Blinded, Interim Data to be Presented at UHMS Annual Scientific Meeting in May 2022Ended Quarter with $32.6 Million in Cash, Cash Equivalents and Marketable SecuritiesRegained Compliance with Nasdaq Bid Price Rule CHARLOTTESVILLE, Va., May 12, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, today announced financial results for the quarter ended March 31, 2022, and provided a business update. Business Updates Completed Dosin

    5/12/22 4:05:00 PM ET
    $DFFN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Diffusion Pharmaceuticals Inc. (Amendment)

    SC 13G/A - CervoMed Inc. (0001053691) (Subject)

    2/14/24 9:23:50 AM ET
    $DFFN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Diffusion Pharmaceuticals Inc.

    SC 13D - CervoMed Inc. (0001053691) (Subject)

    2/9/24 5:02:49 PM ET
    $DFFN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Diffusion Pharmaceuticals Inc.

    SC 13G - CervoMed Inc. (0001053691) (Subject)

    8/28/23 4:02:26 PM ET
    $DFFN
    Biotechnology: Pharmaceutical Preparations
    Health Care